Singapore approves Pfizer bivalent jab for those aged 12 and above | Inquirer News

Singapore approves Pfizer bivalent jab for those aged 12 and above

/ 03:47 PM October 25, 2022

bivalent vaccine

The bivalent vaccine targets both the original strain of the coronavirus and the Omicron BA.4 and BA.5 variants. REUTERS

SINGAPORE — The Health Sciences Authority (HSA) of Singapore has granted interim authorization for Pfizer’s bivalent Covid-19 vaccine for people aged 12 and above.

The bivalent vaccine is authorized as a booster jab for those who have already received their primary series vaccination. It targets both the original strain of the coronavirus and the Omicron BA.4 and BA.5 variants.

Article continues after this advertisement

Official recommendations on the use of this booster vaccine will be issued by the Expert Committee on Covid-19 Vaccination and the Ministry of Health when ready, said HSA in its statement on Tuesday.

FEATURED STORIES

In clinical studies done by Pfizer, the bivalent vaccine has been shown to elicit a stronger immune response against the Omicron BA.1 variant, while still being effective against the original strain of the virus.

RELATED STORIES

Article continues after this advertisement

What to know about ‘bivalent vaccines’ that target Omicron

What is the COVID-19 XBB strain and how will it affect me?

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Pfizer, Singapore

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.